TY - JOUR T1 - Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern JF - medRxiv DO - 10.1101/2021.11.14.21266294 SP - 2021.11.14.21266294 AU - Rajesh Vikkurthi AU - Asgar Ansari AU - Anupama R Pai AU - Someshwar Nath Jha AU - Shilpa Sachan AU - Suvechchha Pandit AU - Bhushan Nikam AU - Anurag Kalia AU - Bimal Prasad Jit AU - Hilal Ahmad Parray AU - Savita Singh AU - Pallavi Kshetrapal AU - Nitya Wadhwa AU - Tripti Shrivastava AU - Poonam Coshic AU - Suresh Kumar AU - Pragya Sharma AU - Nandini Sharma AU - Juhi Taneja AU - Anil K Pandey AU - Ashok Sharma AU - Ramachandran Thiruvengadam AU - Alba Grifoni AU - Shinjini Bhatnagar AU - Daniela Weiskopf AU - Alessandro Sette AU - Pramod Kumar Garg AU - Nimesh Gupta Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/15/2021.11.14.21266294.abstract N2 - The characteristics of immune memory established in response to inactivated SARS-CoV-2 vaccines remains unclear. We determined the magnitude, quality and persistence of cellular and humoral memory responses up to 6 months after vaccination with BBV152/Covaxin. Here, we show that the quantity of vaccine-induced spike- and nucleoprotein-antibodies is comparable to that following natural infection and the antibodies are detectable up to 6 months. The RBD-specific antibodies decline in the range of 3 to 10-fold against the SARS-CoV-2 variants in the order of alpha (B.1.1.7) > delta (B.1.617.2) > beta (B.1.351), with no observed impact of gamma (P.1) and kappa (B.1.617.1) variant. We found that the vaccine induces memory B cells, similar to natural infection, which are impacted by virus variants in the same order as antibodies. The vaccine further induced antigen-specific functionally potent multi-cytokine expressing CD4+ T cells in ∼85% of the subjects, targeting spike and nucleoprotein of SARS-CoV-2. Marginal ∼1.3 fold-reduction was observed in vaccine-induced CD4+ T cells against the beta variant, with no significant impact of the alpha and the delta variants. The antigen-specific CD4+ T cells were populated in the central memory compartment and persisted up to 6 months of vaccination. Importantly the vaccine generated Tfh cells that are endowed with B cell help potential, similar to the Tfh cells induced after natural infection. Altogether, these findings establish that the inactivated virus vaccine BBV152 induces robust immune memory to SARS-CoV-2 and variants of concern, which persist for at least 6 months after vaccination. This study provides insight into the attributes of BBV152-elicited immune memory, and has implication for future vaccine development, guidance for use of inactivated virus vaccine, and booster immunization.Competing Interest StatementNG, AA are listed as inventor on procedure patent application no. 202111003148, submitted by National Institute of Immunology, that covers the use of T-cell qualitative assessment method for vaccine evaluation and adjuvant testing purposes. A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest. Data and materials availability: All data are available in the main text or the extended data.Funding StatementThis work was financially supported by the Science and Engineering Research Board, DST grant (IPA/2020/000077) to NG, Department of Biotechnology (DBT) grant (BT/PR30223/MED/2018) to NG and the core grant of National Institute of Immunology. COVID-19 Bioresource grant (BT/PR40401/BIOBANK/03.2020) to Translational Health Science and Technology Institute. Further support provided in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the Human Research Ethics Committees of National Institute of Immunology and the partnering institutions.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the extended data ER -